@Colecalciferol1: $HUMA - Immediate action plan ...
@Colecalciferol1
16 views
Apr 24, 2026
Advertisement
1
$HUMA - Immediate action plan Humacyte (1/12)
Cc: @MichaelSen, @Fresenius, @FME_Global, @FreseniusKabi, @humacyte
Humacyte is dying. Humacyte is not Lauras little biolab anymore. Humacyte is facing a cash drain of USD 20-30m per quarter, with R&D spending of c. USD 70m per year. Humacyte is stumbling. We, a group of investors with sizable investments, are requesting immediate action by Humacyte to ensure survival, and preserve the healthy core for trauma patients and potentially AV access, and to transform the company towards a Trauma-only production company; we expect the following, immediate action plan to be implemented by the management team (with details in thread):
- Immediate closure of non-core programmes
- Ramp down of production capacity (max. 5k)
- Immediate termination of any employees not related to trauma / AV (until V012)
- Disposal of non-core IP / any programmes not associated with trauma / AV - Potentially via separate entity
- Management downsizing / re-allocation of responsibilities
- Immediate price adjustment to ramp up market penetration (USD 9,999)
- Review of North Carolina facilities - sub-lease any non-core space - legal review of lease agreement
- Downsizing of Board of Directors - specifically Brady W. Dougan
- Renegotiation of Avenue Capital credit facility to unlock conditional tranches
- Increased spend on lobbying (USD 1-2m+)
- Expected value accretion (50-300% upside)
Cc: @MichaelSen, @Fresenius, @FME_Global, @FreseniusKabi, @humacyte
Humacyte is dying. Humacyte is not Lauras little biolab anymore. Humacyte is facing a cash drain of USD 20-30m per quarter, with R&D spending of c. USD 70m per year. Humacyte is stumbling. We, a group of investors with sizable investments, are requesting immediate action by Humacyte to ensure survival, and preserve the healthy core for trauma patients and potentially AV access, and to transform the company towards a Trauma-only production company; we expect the following, immediate action plan to be implemented by the management team (with details in thread):
- Immediate closure of non-core programmes
- Ramp down of production capacity (max. 5k)
- Immediate termination of any employees not related to trauma / AV (until V012)
- Disposal of non-core IP / any programmes not associated with trauma / AV - Potentially via separate entity
- Management downsizing / re-allocation of responsibilities
- Immediate price adjustment to ramp up market penetration (USD 9,999)
- Review of North Carolina facilities - sub-lease any non-core space - legal review of lease agreement
- Downsizing of Board of Directors - specifically Brady W. Dougan
- Renegotiation of Avenue Capital credit facility to unlock conditional tranches
- Increased spend on lobbying (USD 1-2m+)
- Expected value accretion (50-300% upside)
2
$HUMA - Immediate closure of non-core programmes of Humacyte (2/12)
We request that Humacyte focuses solely on trauma sales and production (optional for AV access, in case V012 is successful), and transforms the company into production-only mode:
Specifically we request immediate closure / putting dormant of:
-Peripheral Artery Disease (PAD) programme
- Coronary Artery Bypass Grafting (CABG) programme
- Pediatric heart disease programme
- Biovascular Pancreas (Type 1 Diabetes) programme
- Lung programme
- Urinary Conduit programme
- Tracheal Replacement programme
- Esophageal Replacement programme
- AV Access to be closed in case V012 is unsuccessful
Assuming that c. USD 5m are allocated to remaining AV access works and trauma, we expect an immediate saving of USD 65m per year - All associated employees need to be let go as per today.
We request that Humacyte focuses solely on trauma sales and production (optional for AV access, in case V012 is successful), and transforms the company into production-only mode:
Specifically we request immediate closure / putting dormant of:
-Peripheral Artery Disease (PAD) programme
- Coronary Artery Bypass Grafting (CABG) programme
- Pediatric heart disease programme
- Biovascular Pancreas (Type 1 Diabetes) programme
- Lung programme
- Urinary Conduit programme
- Tracheal Replacement programme
- Esophageal Replacement programme
- AV Access to be closed in case V012 is unsuccessful
Assuming that c. USD 5m are allocated to remaining AV access works and trauma, we expect an immediate saving of USD 65m per year - All associated employees need to be let go as per today.
3
$HUMA - Ramp down of production capacity (max. 5k, 6x LUNAs) (3/12)
Our understanding is that Humacyte has 8 x LUNA200 in operation, each producing 900 ATEVs per year, meaning significant overcapacity as per today. We expect the ramp down to a max capacity of 6x LUNAs, bringing production capacity to c. 5,000 ATEVs (factoring in c. 10% for faulty products etc.).
The remaining LUNAs are to be put in dormant mode - Any remaining employees not necessary need to be let go as per today until production capacity is utilised.
Our understanding is that Humacyte has 8 x LUNA200 in operation, each producing 900 ATEVs per year, meaning significant overcapacity as per today. We expect the ramp down to a max capacity of 6x LUNAs, bringing production capacity to c. 5,000 ATEVs (factoring in c. 10% for faulty products etc.).
The remaining LUNAs are to be put in dormant mode - Any remaining employees not necessary need to be let go as per today until production capacity is utilised.
4
$HUMA - Immediate termination of any employees not related to trauma / AV (until V012, new headcount 75 from 190) (4/12)
Our understanding is that Humacyte has a total workforce of c. 190 (headcount) - thereof: >30 research, >40 operations, >30 engineering, >20 quality assurance, c. 16 associated with sales. Except research (which has been covered already), and except the sales team, we expect a total haircut of 60% across remaining employees to accommodate the new strategic setup.
Total workforce after layoffs of c. 75 (incl. sales team) - assuming total compensation in the biotech sector of c. USD 200k (incl. stock options etc.), overall saving per year c. USD 20m.
Our understanding is that Humacyte has a total workforce of c. 190 (headcount) - thereof: >30 research, >40 operations, >30 engineering, >20 quality assurance, c. 16 associated with sales. Except research (which has been covered already), and except the sales team, we expect a total haircut of 60% across remaining employees to accommodate the new strategic setup.
Total workforce after layoffs of c. 75 (incl. sales team) - assuming total compensation in the biotech sector of c. USD 200k (incl. stock options etc.), overall saving per year c. USD 20m.
5
$HUMA - Disposal of non-core IP / any programmes not associated with trauma / AV - Potentially via separate entity (c. USD 10-15m proceeds) (5/12)
We see two options, with preference for Option 1:
Option 1: Monetisation of the Esophagus patent (extends to 2041), trachea and urinary IP, and CABG preclinical data package (published in JACC). Estimated proceeds yielding USD 10-15m via licensing or outright sale.
Option 2 (not preferred): Foundation of a separate ResearchCo, separate from Humacyte TopCo - ResearchCo needs to seek its own financing arrangement, completely independent from Humacyte. This could act as a parking slot for future developments in above-named programmes, but only (!), when not draining any existing Humacyte management / FTE capacities.
Estimated proceeds from Option 1, as mentioned: USD 10-15m - Can be utilised for severance packages of the FTE scale down etc.
We see two options, with preference for Option 1:
Option 1: Monetisation of the Esophagus patent (extends to 2041), trachea and urinary IP, and CABG preclinical data package (published in JACC). Estimated proceeds yielding USD 10-15m via licensing or outright sale.
Option 2 (not preferred): Foundation of a separate ResearchCo, separate from Humacyte TopCo - ResearchCo needs to seek its own financing arrangement, completely independent from Humacyte. This could act as a parking slot for future developments in above-named programmes, but only (!), when not draining any existing Humacyte management / FTE capacities.
Estimated proceeds from Option 1, as mentioned: USD 10-15m - Can be utilised for severance packages of the FTE scale down etc.
6
$HUMA - Management downsizing / re-allocation of responsibilities (3x Managers, rest to let go) (6/12)
The Humacyte leadership team needs to be reshaped, away from a research-driven, towards an FDA-backed ProductionCo. We expect that the management is consolidated into 3-4 roles (depending on V012 outcome):
1. CEO/CSO - founder-led, with restructuring mandate from the board
2. CFO/COO - combined finance and operations oversight - New / Vacant
3. VP Commercial + Manufacturing - owns the full Symvess value chain
4. VP Clinical/Regulatory (watch list) - manages V012 through readout and potential BLA - Can be terminated in case V012 is not successful
IR, legal, and payroll outsourced. All C-suite cash compensation reduced by 40-50%, replaced with long-dated, milestone-based equity.
The Humacyte leadership team needs to be reshaped, away from a research-driven, towards an FDA-backed ProductionCo. We expect that the management is consolidated into 3-4 roles (depending on V012 outcome):
1. CEO/CSO - founder-led, with restructuring mandate from the board
2. CFO/COO - combined finance and operations oversight - New / Vacant
3. VP Commercial + Manufacturing - owns the full Symvess value chain
4. VP Clinical/Regulatory (watch list) - manages V012 through readout and potential BLA - Can be terminated in case V012 is not successful
IR, legal, and payroll outsourced. All C-suite cash compensation reduced by 40-50%, replaced with long-dated, milestone-based equity.
7
$HUMA - Immediate price adjustment to ramp up market penetration (7/12)
The pricing strategy of Humacyte has been a disaster, and failed miserably. Starting at USD 29,500, down to USD 24,500, and apparently even lower today.
We have said from the start of commercialisation, that Humacyte’s pricing is too high and off market for a new product, which requires thorough explanation, and with surgeons having zero incentive to change their current working mode.
We expect that Humacyte drops the ATEV price to USD 9,999 - which is still well above current treatments, and should enable a quicker market penetration. Once market penetration has been reached, Humacyte can still adjust the pricing upwards incrementally.
This is a significant, strategic misjudgement by the management, which needs to be fixed, urgently.
The pricing strategy of Humacyte has been a disaster, and failed miserably. Starting at USD 29,500, down to USD 24,500, and apparently even lower today.
We have said from the start of commercialisation, that Humacyte’s pricing is too high and off market for a new product, which requires thorough explanation, and with surgeons having zero incentive to change their current working mode.
We expect that Humacyte drops the ATEV price to USD 9,999 - which is still well above current treatments, and should enable a quicker market penetration. Once market penetration has been reached, Humacyte can still adjust the pricing upwards incrementally.
This is a significant, strategic misjudgement by the management, which needs to be fixed, urgently.
8
$HUMA - Review of North Carolina facilities - sub-lease any non-core space - legal review of lease agreement (aim to terminate) (8/12)
Humacyte needs to seek legal advice on whether the lease agreement extension can be unwound, urgently. The agreement should have been with a length of max. 3-5 years, and extended thereafter. Any remaining floor area / office area needs to be subleased to external parties.
Humacyte needs to seek legal advice on whether the lease agreement extension can be unwound, urgently. The agreement should have been with a length of max. 3-5 years, and extended thereafter. Any remaining floor area / office area needs to be subleased to external parties.
9
$HUMA - Downsizing of Board of Directors - specifically Brady W. Dougan (9/12)
The Board of Directors needs to be sized down, and we specifically request the removal of Brady W. Dougan.
Dougan, who is married to Laura and controls shares through Ayabudge LLC, has been a persistent net seller of HUMA stock while serving as a director.
At no point has the company publicly addressed the pattern or provided context beyond standard Form 4 disclosures. For a director married to the CEO, the optics of selling millions while the company raises emergency capital at progressively lower prices are untenable.
We expect the Board of Directors to be production-focused, away from research-driven backgrounds.
The Board of Directors needs to be sized down, and we specifically request the removal of Brady W. Dougan.
Dougan, who is married to Laura and controls shares through Ayabudge LLC, has been a persistent net seller of HUMA stock while serving as a director.
At no point has the company publicly addressed the pattern or provided context beyond standard Form 4 disclosures. For a director married to the CEO, the optics of selling millions while the company raises emergency capital at progressively lower prices are untenable.
We expect the Board of Directors to be production-focused, away from research-driven backgrounds.
10
$HUMA - Renegotiation of Avenue Capital credit facility (10/12)
In December 2025, Humacyte entered into a credit facility with Avenue providing up to USD 77.5m in aggregate.
The headline of USD 77.5m is misleading. The initial USD 40m went straight to debt retirement. The remaining USD 37.5m is conditional - and at the current trajectory (61 units sold, USD 1.6m revenue), Humacyte is unlikely to meet the revenue thresholds required to unlock all tranches.
This is precisely where the restructuring becomes critical: a right-sized Humacyte with a lower price point + volumes has a realistic path to meeting the revenue and liquidity conditions that unlock the additional USD 37.5m (non-dilutive!)
We expect management to proactively engage Avenue to renegotiate the tranche conditions. A focused, lower-burn Humacyte with improving revenue is a better credit than the current sprawling operation - Avenue should recognise this. Unlocking even ie Tranche 2 (USD 12.5m) adds materially to the runway.
In December 2025, Humacyte entered into a credit facility with Avenue providing up to USD 77.5m in aggregate.
The headline of USD 77.5m is misleading. The initial USD 40m went straight to debt retirement. The remaining USD 37.5m is conditional - and at the current trajectory (61 units sold, USD 1.6m revenue), Humacyte is unlikely to meet the revenue thresholds required to unlock all tranches.
This is precisely where the restructuring becomes critical: a right-sized Humacyte with a lower price point + volumes has a realistic path to meeting the revenue and liquidity conditions that unlock the additional USD 37.5m (non-dilutive!)
We expect management to proactively engage Avenue to renegotiate the tranche conditions. A focused, lower-burn Humacyte with improving revenue is a better credit than the current sprawling operation - Avenue should recognise this. Unlocking even ie Tranche 2 (USD 12.5m) adds materially to the runway.
11
$HUMA - Increased spend on lobbying (USD 1-2m+) (11/12)
Humacyte needs to ramp up its lobbying activities, and should dedicate at least USD 1-2m (can be increased with increasing sales) after it reallocates from unproductive activities - Humacyte is a DoD play, and should be treated as such.
Humacyte needs to ramp up its lobbying activities, and should dedicate at least USD 1-2m (can be increased with increasing sales) after it reallocates from unproductive activities - Humacyte is a DoD play, and should be treated as such.
12
$HUMA - Expected value accretion (12/12)
A restructured Humacyte is a profitable Humacyte. Humacyte burns c. USD 8m per month, today.
Under the restructuring outlined annual savings are as follows:
- Programme discontinuation (R&D cut from c. USD 73m to USD 5m): c. USD 65m
- Headcount reduction (190 to 75 FTEs): c. USD 20m
- Manufacturing ramp-down and facility consolidation: c. USD 5-8m
- SG&A rationalisation (outsource IR, legal, payroll; cut exec comp): c. USD 10-15m
- Total annual savings: c. USD 100-108m. Restructured burn rate: c. USD 1.5-2m per month (USD 8m previously)
Available liquidity post-restructuring: USD 25-30m in existing cash, plus USD 10-15m in IP monetisation proceeds (post 5), totalling USD 35-45m. At the new burn rate, this extends the runway to 18-30 months, sufficient to reach the V012.
At scale (5,000 units at USD 9,999), the restructured P&L turns profitable, with Operating income of USD 0-8m (breakeven to profitable)
At USD 12,500 per unit income rises to USD 10-20m,
Two paths forward from the V012 readout:
V012 positive: File supplemental BLA for AV access, a USD 1.8bn market. Raise growth capital from a position of demonstrated clinical and commercial traction - at a fundamentally different valuation to today’s USD 170m market cap. This is a USD 2-5bn outcome.
V012 negative: Humacyte operates as a focused, low-burn, profitable trauma company with an FDA-approved product, military contracts, and international expansion. That profile is a textbook acquisition target for Fresenius, Fresenius Medical Care, Baxter, Medtronic, or J&J at USD 200-500m - well above the current market cap.
Both paths preserve more shareholder value than the current trajectory.
Implied valuation of a restructured Humacyte at
5x revenue / 25x earning: USD 150-250m (low case)
Or: 375m - 650m (high case)
The valuation range post restructuring representing a 50% to 300% upside from today’s market cap of c. USD 170m.
The company and its key shareholders (Fresenius) need to act today.
A restructured Humacyte is a profitable Humacyte. Humacyte burns c. USD 8m per month, today.
Under the restructuring outlined annual savings are as follows:
- Programme discontinuation (R&D cut from c. USD 73m to USD 5m): c. USD 65m
- Headcount reduction (190 to 75 FTEs): c. USD 20m
- Manufacturing ramp-down and facility consolidation: c. USD 5-8m
- SG&A rationalisation (outsource IR, legal, payroll; cut exec comp): c. USD 10-15m
- Total annual savings: c. USD 100-108m. Restructured burn rate: c. USD 1.5-2m per month (USD 8m previously)
Available liquidity post-restructuring: USD 25-30m in existing cash, plus USD 10-15m in IP monetisation proceeds (post 5), totalling USD 35-45m. At the new burn rate, this extends the runway to 18-30 months, sufficient to reach the V012.
At scale (5,000 units at USD 9,999), the restructured P&L turns profitable, with Operating income of USD 0-8m (breakeven to profitable)
At USD 12,500 per unit income rises to USD 10-20m,
Two paths forward from the V012 readout:
V012 positive: File supplemental BLA for AV access, a USD 1.8bn market. Raise growth capital from a position of demonstrated clinical and commercial traction - at a fundamentally different valuation to today’s USD 170m market cap. This is a USD 2-5bn outcome.
V012 negative: Humacyte operates as a focused, low-burn, profitable trauma company with an FDA-approved product, military contracts, and international expansion. That profile is a textbook acquisition target for Fresenius, Fresenius Medical Care, Baxter, Medtronic, or J&J at USD 200-500m - well above the current market cap.
Both paths preserve more shareholder value than the current trajectory.
Implied valuation of a restructured Humacyte at
5x revenue / 25x earning: USD 150-250m (low case)
Or: 375m - 650m (high case)
The valuation range post restructuring representing a 50% to 300% upside from today’s market cap of c. USD 170m.
The company and its key shareholders (Fresenius) need to act today.